Haibin Zhou

Haibin Zhou

Auto-generated profile, based on publicly available information

Haibin Zhou

State Key Laboratory of Bioorganic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai 200032, China

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Cancer Cell
Verified
Journal Article
Closed access
LBLongchuan Bai
Longchuan Bai
HZHaibin Zhou
Haibin Zhou
RXRenqi Xu
Renqi Xu
Yujun ZhaoYujun Zhao
Yujun Zhao
KCKrishnapriya Chinnaswamy
Krishnapriya Chinnaswamy
SWShaomeng Wang
Shaomeng Wang

10 December 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HZHaibin Zhou
Haibin Zhou
LBLongchuan Bai
Longchuan Bai
RXRenqi Xu
Renqi Xu
Yujun ZhaoYujun Zhao
Yujun Zhao
JCJianyong Chen
Jianyong Chen
SWShaomeng Wang
Shaomeng Wang

27 October 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
HZHaibin Zhou
Haibin Zhou
JLJianfeng Lu
Jianfeng Lu
LLLiu Liu
Liu Liu
DBDenzil Bernard
Denzil Bernard
CYChao-Yie Yang
Chao-Yie Yang
SWShaomeng Wang
Shaomeng Wang
The Cullin-RING E3 ubiquitin ligases (CRLs) regulate homeostasis of ~20% of cellular proteins and their activation require neddylation of their cullin subunit. Cullin neddylation is modulated by a scaffolding DCN protein through interactions with both the cullin protein and an E2 enzyme such as UBC12. Here we report the development of DI-591 as a high-affinity, cell-permeable small-molecule inhibitor of the DCN1–UBC12 interaction. DI-591 binds to purified recombinant human DCN1 and DCN2 proteins with Ki values of 10–12 nM, and disrupts the DCN1–UBC12 interaction in cells. Treatment with DI-591 selectively converts cellular cullin 3 into an un-neddylated inactive form with no or minimum effect on other cullin members. Our data firmly establish a previously unrecognized specific role of the DCN1–UBC12 interaction for cellular neddylation of cullin 3. DI-591 is an excellent probe compound to investigate the role of the cullin 3 CRL ligase in biological processes and human diseases.

17 January 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HZHaibin Zhou
Haibin Zhou
LLLiu Liu
Liu Liu
JHJing Huang
Jing Huang
DBDenzil Bernard
Denzil Bernard
HKHacer Karatas
Hacer Karatas
SWShaomeng Wang
Shaomeng Wang

5 June 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LBLongchuan Bai
Longchuan Bai
JCJianfang Chen
Jianfang Chen
DMDonna McEachern
Donna McEachern
LLLiu Liu
Liu Liu
HZHaibin Zhou
Haibin Zhou
SWShaomeng Wang
Shaomeng Wang
Bcl-2 and Bcl-xL are critical regulators of apoptosis that are overexpressed in a variety of human cancers and pharmacological inhibition of Bcl-2 and Bcl-xL represents a promising strategy for cancer treatment. Using a structure-based design approach, we have designed BM-1197 as a potent and efficacious dual inhibitor of Bcl-2 and Bcl-xL. BM-1197 binds to Bcl-2 and Bcl-xL proteins with Ki values less than 1 nM and shows >1,000-fold selectivity over Mcl-1. Mechanistic studies performed in the Mcl-1 knockout mouse embryonic fibroblast (MEF) cells revealed that BM-1197 potently disassociates the heterodimeric interactions between anti-apoptotic and pro-apoptotic Bcl-2 family proteins, concomitant with conformational changes in Bax protein, loss of mitochondrial membrane potential and subsequent cytochrome c release to the cytosol, leading to activation of the caspase cascade and apoptosis. BM-1197 exerts potent growth-inhibitory activity in 7 of 12 small cell lung cancer cell lines tested and induces mechanism-based apoptotic cell death. When intravenously administered at daily or weekly in H146 and H1963 small-cell lung cancer xenograft models, it achieves complete and long-term tumor regression. Consistent with its targeting of Bcl-xL, BM-1197 causes transit platelet reduction in mice. Collectively, our data indicate that BM-1197 is a promising dual Bcl-2/Bcl-xL inhibitor which warrants further investigation as a new anticancer drug.

4 July 2007 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
HZHai-Bin Zhou
Hai-Bin Zhou
GLGuan-Sai Liu
Guan-Sai Liu
ZYZhu-Jun Yao
Zhu-Jun Yao